The double burden: A new-age pandemic meets an ancient infection

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 108, Issue 11, 2014, Pages 676-678

  Bridson, Tahnee L ^a   Govan, Brenda L ^a   Norton, Robert E ^a,b   Schofield, Louis ^a,c   Ketheesan, Natkunam ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Diabetes; Infectious diseases; Susceptibility; Tuberculosis; Type 2 diabetes

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12;

ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; COMORBIDITY; DIABETES MELLITUS; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATORY CELL; INNATE IMMUNITY; NONHUMAN; OXIDATIVE STRESS; PANDEMIC; TUBERCULIN TEST; TUBERCULOSIS; COST OF ILLNESS; DEVELOPING COUNTRY; DIABETES MELLITUS, TYPE 2; DISEASE PREDISPOSITION; FEMALE; IMMUNOLOGY; MALE;

COST OF ILLNESS; DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 2; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; MALE; PANDEMICS; TUBERCULOSIS;

EID: 84913600987     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/tru135     Document Type: Article

References (23)

1. Kaufmann SH. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann Rheum Dis 2002;61(Supp 2):ii54-8.
2. Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol 2014;44:617-26.
3. Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 2012;367:931-6.
4. Restrepo BI, Schlesinger LS. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. Tuberculosis (Edinb) 2013;93:Suppl:S10-4.
5. Hodgson KA, Govan BL, Walduck AK et al. Impaired early cytokine responses at the site of infection in a murine model of type 2 diabetes and melioidosis comorbidity. Infect Immun 2013;81:470-7.
6. IDF. IDF Diabetes Atlas 5th Edition. Brussels, Belgium: International Diabetes Federation; 2011. http://www.idf.org/diabetesatlas [accessed March 2014].
7. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008;5:e152.
8. Viswanathan V, Vigneswari A, Selvan K et al. Effect of diabetes on treatment outcome of smear-positive pulmonary tuberculosis-a report from South India. J Diabetes Complications 2014;28:162-5.
9. Viswanathan V, Kumpatla S, Aravindalochanan V et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. PLoS One 2012;7:e41367.
10. Leegaard A, Riis A, Kornum JB et al. Diabetes, glycemic control, and risk of tuberculosis: a population-based case-control study. Diabetes Care 2011;34:2530-5.
11. Baker MA, Harries AD, Jeon CY et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011;9:81.
12. Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax 2013;68:214-20.
13. Faurholt-Jepsen D, Range N, PrayGod G et al. Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Trop Med Int Health 2013;18:822-9.
14. Vlassara H, Cai W, Crandall J et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002;99:15596-601.
15. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107.
16. Yamashiro S, Kawakami K, Uezu K et al. Lower expression of Th1-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis. Clin Exp Immunol 2005;139:57-64.
17. Kumar NP, Sridhar R, Banurekha VV et al. Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. J Infect Dis 2013;208:739-48.
18. Vallerskog T, Martens GW, Kornfeld H. Diabetic mice display a delayed adaptive immune response to Mycobacterium tuberculosis. J Immunol 2010;184:6275-82.
19. Hur YG, Crampin AC, Chisambo C et al. Identification of immunological biomarkers which may differentiate latent tuberculosis from exposure to environmental nontuberculous mycobacteria in children. Clin Vaccine Immunol 2014;21:133-42.
20. Pai M, Denkinger CM, Kik SV et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014;27:3-20.
21. Lee PH, Lin HC, Huang AS et al. Diabetes and risk of tuberculosis relapse: nationwide nested case-control study. PLoS One 2014;9: e92623.
22. Mathews CE, Brown EL, Martinez PJ et al. Impaired function of antibodies to pneumococcal surface protein A but not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus. Clin Vaccine Immunol 2012;19:1360-9.
23. Weiner J 3rd, Kaufmann SH. Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med 2014;275:467-80.